XML 101 R34.htm IDEA: XBRL DOCUMENT v3.25.4
REVENUES (Tables)
12 Months Ended
Dec. 31, 2025
Revenue from Contract with Customer [Abstract]  
Schedule of Disaggregation of Revenue

The following table presents sales by operating segment disaggregated based on product category and geographic region for the years ended December 31, 2025, 2024 and 2023 (in thousands).

2025

2024*

2023*

  ​ ​

United States

  ​ ​

International

  ​ ​

Total

  ​ ​

United States

  ​ ​

International

  ​ ​

Total

  ​ ​

United States

  ​ ​

International

  ​ ​

Total

Cardiovascular

 

 

 

  ​

 

  ​

 

  ​

 

  ​

  ​

 

  ​

 

  ​

Peripheral Intervention

$

341,941

$

237,899

$

579,840

$

312,667

$

220,103

$

532,770

$

280,817

$

202,448

$

483,265

Cardiac Intervention

 

187,355

261,559

 

448,914

 

147,961

220,990

 

368,951

 

143,715

212,935

 

356,650

Custom Procedural Solutions

 

128,570

80,763

 

209,333

 

122,156

77,877

 

200,033

 

113,839

79,878

 

193,717

OEM

 

182,716

22,239

 

204,955

 

166,160

33,830

 

199,990

 

154,232

32,696

 

186,928

Total

 

840,582

602,460

 

1,443,042

 

748,944

 

552,800

 

1,301,744

 

692,603

 

527,957

 

1,220,560

 

 

Endoscopy

Endoscopy Devices

 

68,884

 

3,980

 

72,864

 

51,836

 

2,934

 

54,770

 

34,386

2,420

 

36,806

Total

$

909,466

$

606,440

$

1,515,906

$

800,780

$

555,734

$

1,356,514

$

726,989

$

530,377

$

1,257,366

*Commencing January 1, 2025, we reorganized our sales teams and product categories to include revenues from the sale of our spine devices under our OEM product category. Revenue figures for 2024 and 2023 have been recast to reflect this realignment of our portfolio of spine products, representing approximately $22.6 million and $22.4 million in revenue, respectively, within the OEM product category to provide comparability between the reported periods.